
Savara (SVRA) Stock Forecast & Price Target
Savara (SVRA) Analyst Ratings
Bulls say
Savara Inc. is progressing towards the submission of its Biologics License Application (BLA) for molgramostim, which targets autoimmune pulmonary alveolar proteinosis (aPAP), a rare respiratory disease. The company anticipates that approximately 85% of the estimated 3,600 diagnosed aPAP patients will be eligible for treatment at launch, indicating a substantial potential patient base. Additionally, the strong engagement shown by patients, with 100% participation in the 96-week open-label period of the IMPALA-2 study, suggests considerable interest in the product, enhancing the company's market prospects and overall outlook.
Bears say
Savara Inc reported a net loss of $24.2 million, or $0.11 per share, for the third quarter of 2024, highlighting ongoing financial challenges. Key concerns driving a negative outlook include the risks associated with potential failure to secure regulatory approval, the possibility of a smaller than expected commercial opportunity due to market size, competition, and pricing pressures, as well as uncertainties surrounding future clinical study outcomes. Additionally, there is noted physician reluctance regarding patient testing, further impacting the prospects for successful product adoption and revenue generation.
This aggregate rating is based on analysts' research of Savara and is not a guaranteed prediction by Public.com or investment advice.
Savara (SVRA) Analyst Forecast & Price Prediction
Start investing in Savara (SVRA)
Order type
Buy in
Order amount
Est. shares
0 shares